Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAIN Act Update: Antibiotic Pipeline Problem is Politically Ripe

This article was originally published in RPM Report

Executive Summary

As the PDUFA reauthorization process approaches, antibiotic drug development is poised as an area to see some legislative action. A recent workshop highlighted the interest in such action and evidence it may be effective.

You may also be interested in...



GAIN Is Great: Now Who Gets the Benefits?

Congress is set on enacting a package of antibiotic development incentives—but needs to sort out how best to define the targets.

Antibiotic Incentive Bill Reintroduced: Industry Hopes for 2012 Enactment

The bill focuses on particularly virulent, resistant pathogens and also includes priority review designations and review of FDA guidelines.

Antibiotic Early Endpoints: FDA Looking At Patient Observations

An effort to identify early biomarkers of antibiotic efficacy is turning toward patient assessments of drug activity. FDA and industry scientists are both participating in the biomarker effort. The attention to patient observations reflects a growing interest at FDA.

Related Content

UsernamePublicRestriction

Register

PS080891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel